We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Becton Dickinson and Company | NYSE:BDX | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.57 | 0.24% | 237.15 | 239.57 | 236.1098 | 237.86 | 1,119,947 | 22:35:27 |
From May 2019 to May 2024
By Chris Wack
Henry Schein Inc. said Wednesday it will serve as the exclusive distributor in the U.S. of a second point-of-care rapid test kit that can detect antibodies associated with Covid-19 in as few as 15 minutes.
The health-care technology company said it is working with Becton Dickinson & Co. and BioMedomics, a privately held clinical diagnostics company, to make the test kits available to health-care professionals.
The BioMedomics test analyzes blood, serum or plasma samples for the presence of Immunoglobulin M and Immunoglobulin G antibodies associated with the coronavirus. The test is completed in four steps. The results can be read in 15 minutes.
The company said it is also a participant in the White House's Covid-19 Supply Chain Task Force, and has worked with the Strategic National Stockpile to deliver personal protective equipment to Covid-19 testing sites, and is working with the Federal Emergency Management Agency to source and deliver critical supplies quickly.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 01, 2020 07:30 ET (11:30 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Becton Dickinson Chart |
1 Month Becton Dickinson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
